Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Short Communications

Germ Line BAX Alterations Are Infrequent in Li-Fraumeni Syndrome

Jason W. Barlow, Marieke Mous, Joe C. Wiley, Jennifer M. Varley, Guillermina Lozano, Louise C. Strong and David Malkin
Jason W. Barlow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marieke Mous
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joe C. Wiley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer M. Varley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillermina Lozano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise C. Strong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Malkin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published August 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Multiple early-onset tumors, frequently associated with germ line TP53 mutations characterize the Li-Fraumeni familial cancer syndrome (LFS). LFS-like (LFS-L) families have lower rates of germ line TP53 alteration and do not meet the strict definition of LFS. This study examined 7 LFS cell lines and 30 LFS and 36 LFS-L primary leukocyte samples for mutations in the proapoptotic p53-regulated gene BAX. No germ line BAX mutations were found. A known BAX polymorphism was observed, yet there was no correlation between polymorphism frequency and TP53 status in either LFS or LFS-L. In summary, alterations of BAX are not responsible for cancers in TP53 wild-type LFS or LFS-L families.

Introduction

Li-Fraumeni Syndrome and p53

The Li-Fraumeni syndrome (LFS) defines a rare familial aggregation of cancers (1), which characteristically includes brain tumors, leukemia, osteosarcomas, soft tissue sarcomas, adrenocortical carcinomas, and breast cancer (1, 2). LFS is inherited as an autosomal dominant disorder with high penetrance; 90% of carriers develop cancer by age 70 years (3). Additionally, LFS patients frequently develop multiple primary tumors (4). More than 60% of patients with LFS harbor germ line mutations of the TP53 tumor suppressor gene (5, 6). LFS-like (LFS-L) families have similar cancer histories but do not meet the strict definition of LFS (cancer under age 45 years or the presence of a sarcoma). Typically, the LFS-L families exhibit an incidence of germ line TP53 alteration of only 20% (6). The lack of germ line TP53 mutations in a significant proportion of LFS patients suggests that other genetic alterations may be important in determining their susceptibility to cancer. Recent studies have essentially excluded a significant role in the genesis of cancer in LFS families for CDKN2A, PTEN, BCL10, and TP63 (7-11). The role of CHEK2 in LFS is still not clear, although current work suggests that it is altered only in very rare families (12-14). Deletions, intronic mutations, and promoter region defects of TP53 have rarely been reported (15-17). Furthermore, the clinical description of LFS-L families suggests that variations in phenotype may complicate refinement of the genotype (6). This study proposes that germ line mutations in genes regulated by p53, such as BAX, may lead to the cancers in the LFS and LFS-L families without germ line TP53 mutations. Furthermore, aberrant expression of these proteins might be involved in the transformation of LFS-derived cell lines. BAX (BCL2-associated x protein), a proapoptotic protein that antagonizes the survival function of BCL2, is also involved in regulating mitochondrial membrane permeability. In normal cells, BAX is a cytosolic monomer (18). When activated, BAX integrates into the outer mitochondrial membrane and oligomerizes, allowing the release of cytochrome c, which binds APAF1 and subsequently activates the initiator caspase-9 (19, 20). p53 positively regulates BAX (21). Mutations of BAX have only rarely been reported as somatic alterations in human malignancy (22, 23). A BAX frameshift mutation resulting from a repeat of seven or nine guanine residues instead of the normal eight residues has been identified in 21 of 41 colon adenocarcinomas of the multiple mutator phenotype (23). Two missense mutations, a G67R alteration found in a T-cell acute lymphoblastic leukemia line and a G108V alteration found in a Burkitt lymphoma cell line, have also been reported (24). However, their potential role in the development of cancer in the presence or absence of germ line TP53 mutations in LFS has not been explored previously. We postulated that germ line alteration of the p53 downstream gene BAX could be responsible for the cancer-prone phenotype of LFS families harboring wild-type (WT) TP53.

Materials and Methods

Genomic DNA from LFS Cell Lines and Primary Lymphocytes

One fibroblast and 11 lymphoblastoid cell lines derived from LFS patients or unaffected family members were the primary source of RNA. Lymphoblastoid cell lines, as well as primary lymphocytes, were the source of genomic DNA for a total of 37 LFS and 36 LFS-L patients.

BAX Mutation Analysis: Subcloning and Sequencing

DNA was extracted from peripheral blood leukocytes from LFS or LFS-L patients or from cell lines of LFS patients. Single-strand conformational polymorphism was preformed on this DNA using a protocol and primers from Chou et al. (22). Samples that were shifted were gel purified and cloned into a t-tailed pBluescript vector, transfected into competent Escherichia coli, and sequenced using primers specific to the vector and the standard dideoxy termination method as described in the Sequenase version 2.0 DNA sequencing kit (Amersham, Piscataway, NJ).

Statistical Analysis

Allelic frequencies of the BAX polymorphism 14 bp 3′ of exon 3 were calculated from the genotype frequencies determined by single-strand conformational polymorphism. χ2 analysis was done to determine if the observed allele frequencies were significantly different from those reported by Centre d'Etude de Polymorphism Humain (CEPH). The significance level of each test was taken to be 0.05.

Results

BAX Single-Strand Conformational Polymorphism

Thirty-seven LFS and 36 LFS-L individuals were screened for BAX alterations. Among the LFS samples, 17 carry WT TP53 and 20 are mutant. Among the LFS-L samples, 29 have WT TP53 and 7 are mutant (Table 1). Band shifts were detected in exons 1, 5, and 6 in a total of 3, 1, and 12 samples, respectively; however, bidirectional direct sequencing of these samples showed no mutations. Single-strand conformational polymorphism analysis of exons 2 and 3 showed numerous band shifts resulting from a known C/T polymorphism 14 bp 3′ of exon 3. This polymorphism occurs at a frequency of 32% of alleles in 31 CEPH individuals (22). Subcloning and sequencing of the samples and control DNA confirmed the presence of this polymorphism. The known BAX frameshift mutation reported in colon cancers of the microsatellite mutator phenotype was not observed, nor were any other alterations (23).

View this table:
  • View inline
  • View popup
Table 1.

Allele frequency of the intronic BAX polymorphism in LFS, LFS-L, and control CEPH DNA samples

χ2 Analysis of the BAX Polymorphism

χ2 analysis of the observed allele frequencies of the BAX polymorphism indicated no significant difference between the 37 LFS and the 36 LFS-L samples analyzed (χ2 = 0.446 and 0.266, respectively; Table 1A). A χ2 of 3.84 is required for significance at 0.05. When segregated into WT TP53 (n = 17) or mutant TP53 (n = 20) groups and compared with the CEPH sample, the LFS samples were not significantly different (χ2 = 0.170 and 2.190, respectively; Table 1B). Similar analysis of LFS-L samples segregated into WT TP53 (n = 29) or mutant TP53 (n = 7) groups, and compared with the CEPH sample, LFS-L WT TP53 and mutant TP53 samples were not significantly different (χ2 = 0.015 and 2.019, respectively; Table 1C).

Discussion

To date, several genes have been examined in an attempt to explain the inherited familial cancer predisposition in TP53 WT Li-Fraumeni families. To add to the current body of work, this article examines the status of BAX in individuals with LFS or LFS-L with and without germ line TP53 mutations. This p53 downstream gene is partially responsible for the p53 regulation of apoptosis.

Our results indicate an absence of BAX mutations in LFS or LFS-L samples with either WT or mutant TP53, suggesting that germ line alterations of BAX are not responsible for the cancer-prone phenotype of LFS or LFS-L. It is possible that the observed polymorphism has a role in altering BAX RNA stability or is involved in the alternatively spliced transcript BAXδ, in which exon 3 is excluded from the mRNA and protein product resulting in the removal of the BH3 domain (25). The significance of the BAXδ transcript is unknown, although BH3-only proteins are critical to inducing apoptosis (26). The BH3 domain along with BH1 and BH2 form a hydrophobic pocket that is critical for BAX function (27). BAXδ may lack such a pocket and fail to be activated in response to an apoptotic signal, although this has not been shown to date. To determine if the incidence of the polymorphism correlates with the predisposition of LFS, χ2 analysis of the observed frequency of the BAX polymorphism, C/T 14 bp 3′ of exon 3, was done. The results indicate that the frequency of the polymorphism among LFS and LFS-L samples is not significantly different from the frequency of a CEPH control population (Table 1). Based on these results, it seems that the molecular defect responsible for the inherited cancer syndrome in LFS families lacking TP53 mutations is not an alteration of BAX. Similar studies of other genes such as CDKN2A, PTEN, BCL10, CHK2, and TP63 have generally failed to explain the familial cancer predisposition in these families (7-14).

Several novel downstream target genes of p53 including NOXA, p53AIP1, and PIDD have been identified, but it is not yet known if these proteins are involved in oncogenesis. Perhaps proteins that functionally interact with the p53 protein such as p33 and JMY will provide new and interesting candidates to explain these cancers. Proteins upstream of p53 such as ATM, ATR, and Chk2 phosphorylate p53, regulating its function. Recently, germ line alterations of CHEK2 have been implicated in one LFS TP53 WT family (12); however, these findings have not been further substantiated in families meeting the strict definition of LFS (13, 14). Additionally, PIN1, an enzyme capable of altering protein conformation, has recently been shown to activate p53 in response to genotoxic agents and may represent a reasonable target to account for poor p53 function. Perhaps there are several genes each responsible for a handful of cancer families, with TP53 responsible for the largest proportion. Such a finding would be confirmation of the hypothesis that newly discovered tumor suppressors are unlikely to be as widely involved in cancer as TP53. Rather, they are likely to occur infrequently and in special cases where the gene is occasionally involved as a tumor suppressor in a cell type–specific or tissue-specific fashion (28).

Acknowledgments

We thank Dr. Linda Penn (Ontario Cancer Institute, Toronto, Ontario, Canada) for providing Rat1 cells with and without a human BCL2 transgene, Gillian Bromfield for providing a p21WAF1/CIP1 positive control, and Susan Quesnel for technical assistance with cell lines and Western blotting.

Footnotes

  • Grant support: National Cancer Institute of Canada from funds raised from the Terry Fox Foundation; National Cancer Institute of Canada, Canadian Cancer Society (D. Malkin); and Hospital for Sick Children RESTRACOM program and Ontario Graduate Scholarship program (J.W. Barlow).

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted March 16, 2004.
    • Received December 10, 2003.
    • Revision received February 19, 2004.

References

  1. ↵
    Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969a;43:1365-73.
  2. ↵
    Li FP. Cancer families: Human models of susceptibility to neoplasia. Cancer Res 1988;48:5381-6.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Lustbader ED, Williams WR, Bondy ML, Strom S, Strong LC. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 1992;54:344-56.
    OpenUrl
  4. ↵
    Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-11.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Malkin D, Li FP, Strong LC, et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Varley JM, McGown G, Thorncroft M, et al. Germline mutations of TP53 in Li-Fraumeni families: An extended study of 39 families. Cancer Res 1997;57:3245-52.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Portwine C, Lees J, Verselis S, Li FP, Malkin D. Absence of germline p16(INK4a) alterations in p53 wild type Li-Fraumeni syndrome families. J Med Genet 2000;37:1-4.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Burt EC, McGown G, Thorncroft M, James LA, Birch JM, Varley JM. Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li-Fraumeni syndrome. Br J Cancer 1999;80:9-10.
    OpenUrlCrossRefPubMed
  9. ↵
    Brown LT, Sexsmith E, Malkin D. Identification of a novel PTEN intronic deletion in Li-Fraumeni syndrome and its effect on RNA processing. Cancer Genet Cytogenet 2000;123:65-8.
    OpenUrlCrossRefPubMed
  10. ↵
    Stone JG, Eeles RA, Sodha N, Murday V, Sheriden E, Houlston RS. Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in BCL10. Cancer Lett 1999;147:181-5.
    OpenUrlCrossRefPubMed
  11. ↵
    Bougeard G, Limacher J, Martin C, et al. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet 2001;38:253-6.
    OpenUrlFREE Full Text
  12. ↵
    Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Lee SB, Kim SH, Bell DW, et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res 2001;61:8062-7.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Vahteristo P, Tamminen A, Karvinen P, et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001;61:5718-22.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Plummer SJ, Santibanez-Koref M, Kurosaki T, et al. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family. Oncogene 1994;9:3273-80.
    OpenUrlPubMed
  16. ↵
    Barel D, Avigad S, Mor C, Fogel M, Cohen IJ, Zaizov R. A novel germ-line mutation in the noncoding region of the p53 gene in a Li-Fraumeni family. Cancer Genet Cytogenet 1998;103:1-6.
    OpenUrlCrossRefPubMed
  17. ↵
    Avigad S, Barel D, Blau O, et al. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene 1997;14:1541-5.
    OpenUrlCrossRefPubMed
  18. ↵
    Hsu Y-T, Youle RJ. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem 1998;273:10777-83.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Antonsson B, Montessuit S, Sanchez B, Martinou JC. Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 2001;276:11615-23.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Mikhailov V, Mikhailova M, Pulkrabek DJ, Dong Z, Venkatachalam MA, Saikumar P. Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane. J Biol Chem 2001;276:18361-74.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human BAX gene. Cell 1995;80:293-9.
    OpenUrlCrossRefPubMed
  22. ↵
    Chou D, Miyashita T, Mohrenweiser HW, et al. The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 1996;88:136-40.
    OpenUrlCrossRefPubMed
  23. ↵
    Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-9.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Meijerink JPP, Smeters TFCM, Sloetjes AW, Linders EHP, Mensink EJBM. BAX mutations in cell lines derived from hematological malignancies. Leukaemia 1995;9:1828-32.
    OpenUrlPubMed
  25. ↵
    Apte SS, Mattei M, Olsen BR. Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAXδ. Genomics 1995;26:592-4.
    OpenUrlCrossRefPubMed
  26. ↵
    Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56.
    OpenUrlCrossRefPubMed
  27. ↵
    Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000;103:645-54.
    OpenUrlCrossRefPubMed
  28. ↵
    Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 13 (8)
August 2004
Volume 13, Issue 8
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Germ Line BAX Alterations Are Infrequent in Li-Fraumeni Syndrome
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Germ Line BAX Alterations Are Infrequent in Li-Fraumeni Syndrome
Jason W. Barlow, Marieke Mous, Joe C. Wiley, Jennifer M. Varley, Guillermina Lozano, Louise C. Strong and David Malkin
Cancer Epidemiol Biomarkers Prev August 1 2004 (13) (8) 1403-1406;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Germ Line BAX Alterations Are Infrequent in Li-Fraumeni Syndrome
Jason W. Barlow, Marieke Mous, Joe C. Wiley, Jennifer M. Varley, Guillermina Lozano, Louise C. Strong and David Malkin
Cancer Epidemiol Biomarkers Prev August 1 2004 (13) (8) 1403-1406;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Cancer Predisposition Gene Mutations and Pancreatic Cancer
  • Statin Use and Breast Cancer Risk
  • Tamoxifen and Longitudinal Mammographic Density Change
Show more Short Communications
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement